Apalutamide Plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study.

Creative Commons License

Agarwal N., McQuarrie K., Bjartell A., Chowdhury S., Pereira de Santana Gomes A. J., Chung B. H., ...Daha Fazla

The Journal of urology, cilt.206, ss.914-923, 2021 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 206
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1097/ju.0000000000001841
  • Dergi Adı: The Journal of urology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, BIOSIS, CAB Abstracts, EMBASE, Gender Studies Database, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.914-923
  • Anahtar Kelimeler: apalutamide, quality of life, prostatic neoplasms, neoplasm metastasis, CHEMOTHERAPY-NAIVE PATIENTS, ABIRATERONE ACETATE, DOUBLE-BLIND, PREDNISONE, PATIENT, MEN
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

Purpose: We performed an exploratory analysis of prostate cancer-related pain and fatigue on health-related quality of life in patients with metastatic castration-sensitive prostate cancer receiving apalutamide (240 mg/day) or placebo, with continuous androgen deprivation therapy (ADT), in the phase 3, randomized, double-blind, placebo controlled TITAN trial (NCT02489318).